A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis

Michels Gina M.; Ramsey Deborah S.; Walsh Kelly F.; Martinon Olivier M.; Mahabir Sean P.; Hoevers Jacquelien D.; Walters Rodney R.; Dunham Steven A.

首页> 外文期刊>Veterinary Dermatology >A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis

【24h】

A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis

机译：Lokivetmab（ZTS-00103289）（一种犬化的抗犬IL-31单克隆抗体）在患有特应性皮炎的客户拥有的狗中的盲，随机，安慰剂对照剂量确定试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundPruritus is the hallmark clinical sign of atopic dermatitis (AD) in dogs. Lokivetmab, a caninized anti-canine IL-31 monoclonal antibody, reduced pruritus and associated inflammatory skin lesions in a proof-of-concept study in dogs with AD.

机译：背景Pruritus是犬特应性皮炎（AD）的标志性临床体征。 Lokivetmab是一种犬源化抗犬IL-31单克隆抗体，在患有AD犬的概念验证研究中，减少了瘙痒和相关的炎症性皮肤损害。

著录项

来源
《Veterinary Dermatology》 |2016年第6期|共12页
作者
Michels Gina M.; Ramsey Deborah S.; Walsh Kelly F.; Martinon Olivier M.; Mahabir Sean P.; Hoevers Jacquelien D.; Walters Rodney R.; Dunham Steven A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类皮肤病;
关键词

相似文献

外文文献
专利

1. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis [J] . Michels Gina M., Ramsey Deborah S., Walsh Kelly F., Veterinary Dermatology . 2016,第6期

机译：Lokivetmab（ZTS-00103289）（一种犬化的抗犬IL-31单克隆抗体）在患有特应性皮炎的客户拥有的狗中的盲，随机，安慰剂对照剂量确定试验
2. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis [J] . Michels Gina M., Walsh Kelly F., Kryda Kristina A., Veterinary Dermatology . 2016,第6期

机译：Lokivetmab（ZTS-00103289）（一种犬化的抗犬IL-31单克隆抗体）在特应性皮炎客户养狗中的安全性的盲目的，随机，安慰剂对照试验
3. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel (R)) in client-owned dogs with atopic dermatitis [J] . Cosgrove Sallie B., Wren Jody A., Cleaver Dawn M., Veterinary Dermatology . 2013,第6期

机译：Janus激酶抑制剂oclacitinib（Apoquel（R））在特应性皮炎的客户拥有的狗中的功效和安全性的双盲，随机，安慰剂对照试验
4. A systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008-2011 update [C] . Thierry Olivry, Petra Bizikova World Congress of Veterinary Dermatology . 2013

机译：对狗的预防或治疗特应性皮炎的随机对照试验进行系统综述：2008-2011更新
5. A randomized, double-blind, placebo-controlled phase II trial to examine the effect of polyphenon E on endogenous hormone levels [D] . Ling, Chen 2009

机译：一项随机，双盲，安慰剂对照的II期临床试验，用于研究多肽E对内源激素水平的影响
6. A blinded randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs [O] . Peter R Little, Vickie L King, Kylie R Davis, -1

机译：一项盲法随机化的临床试验比较了奥卡替尼和环孢素在控制自养犬中特应性皮炎的功效和安全性
7. A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client‐owned dogs with allergic dermatitis [O] . Leen Van Brussel, Hilde Moyaert, Monica Escalada, 2021

机译：一种掩盖的随机临床试验，评估Lokivetmab的疗效和安全性与具有过敏性皮炎的客户所有犬的盐水控制相比

A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis

摘要

著录项

相似文献

相关主题

期刊订阅